Ask about this productRelated genes to: WDR54 Blocking Peptide
- Gene:
- WDR54 NIH gene
- Name:
- WD repeat domain 54
- Previous symbol:
- -
- Synonyms:
- FLJ12953
- Chromosome:
- 2p13.1
- Locus Type:
- gene with protein product
- Date approved:
- 2005-02-08
- Date modifiied:
- 2019-03-21
Related products to: WDR54 Blocking Peptide
Related articles to: WDR54 Blocking Peptide
- Hepatocellular carcinoma (HCC) is a major health threat worldwide. This study found that WDR54 is overexpressed in liver cancer tissues and is inversely correlated with patient prognosis. Through comprehensive cell biology experiments, we demonstrated that WDR54 plays a pivotal role in promoting the malignant proliferation and metastasis of HCC. Further molecular biology investigations, including transcriptome sequencing, revealed that WDR54 exerts its biological effects by modulating the NF-κB signaling pathway. Specifically, WDR54 interacts with RBBP5 to enhance the transcription of p65, thereby promoting HCC proliferation and metastasis. Additionally, the potential impact of WDR54 on tumor cell metabolism and tumor heterogeneity is explored. The findings of this study deepen our understanding of the molecular pathology of liver cancer and lay a foundation for future clinical applications. - Source: PubMed
Publication date: 2025/11/15
Zhai HengyongDu YanpingHe HongShen XiaozhouHu Duanmin - Oral squamous cell carcinoma (OSCC) accounts for over 90% of oral malignancies, with more than 370 000 new cases and approximately 188 000 deaths annually worldwide. In China, there are roughly 65 000 new cases and 35 000 deaths each year, showing a significant upward trend compared with 2015 statistics. Despite continuous advancements in treatment modalities, the 5-year survival rate remains stagnant at 50%-60%, where tumor heterogeneity and therapy resistance persist as fundamental barriers to precision oncology. To address these critical challenges, this study established a standardized bioban-king protocol for OSCC patient-derived organoids (PDOs) (Patent: Method for constructing an oral squamous cell carcinoma organoid bank, ZL202311378598.3). Through groundbreaking optimization of culture media, enzymatic digestion kinetics, and stepwise cryopreservation, we achieved a biobanking success rate exceeding 95% and pioneered synchronous cultivation of matched primary tumors, lymph node metastases, and adjacent normal mucosa from individual patients, preserving spatial heterogeneity and stromal interactions. Leveraging this platform, we developed high-throughput drug screening: Quantified heterogeneity-driven differential chemoresponse using adenosine triphosphate (ATP)-based viability assays; We discovered resistance mechanisms: Identified sialylated cancer IgG (SIA-cIgG)-mediated cis-platin resistance (primary/secondary) through PTPN13 suppression, with anti-SIA-cIgG combination therapy demonstrating synergistic efficacy. Besides, we elucidated metastatic drivers: CRISPR-Cas9-edited organoids revealed WDR54 promoted metastasis H3K4me3/H4K16ac epigenetic reprogramming, activating epithelial-mesenchymal plasticity (EMP) and inducing partial epithelial-mesenchymal transition (pEMT). This "holographic patient-mirroring" platform provided unprecedented resolution for OSCC precision therapy and had been formally incorporated into the Chinese Stomatological Association Technical Guidelines (Technical guideline for establishing patient-derived oral squamous cell carcinoma organoid banks, CHSA 2024-08). Future integration of immune-competent organoids, 3D-bioprinted vasculature, and multi-omics-AI systems will accelerate personalized oncology. These innovations will accelerate clinical translation of personalized therapeutic regimens, ultimately bridging the gap between bench research and bedside application. - Source: PubMed
Xie ShangWang LumingZhang XinyuanFeng QiushiXia YangyangDai ZiweiShan XiaofengCai Zhigang - Human induced pluripotent stem cells (iPSCs) have transformed biomedical research by enabling the generation of diverse cell types from accessible somatic tissues. However, certain fundamental biological properties, such as the genetic and epigenetic determinants of iPSC proliferation, remain poorly characterized. We measured the growth of iPSC lines derived from 602 unique donors using high-throughput time-lapse imaging, quantified proliferation through a growth Area-Under-the-Curve (gAUC) phenotype, and correlated gAUC with the gene expression and genotype of the cell lines. We identified 3,091 genes associated with gAUC, many of which are well established regulators of cell proliferation. We also found that rare deleterious variants in were associated with reduced iPSC growth and that was differentially expressed with respect to gAUC. Although no common variants showed a genome-wide association with gAUC, iPSC lines from monozygotic twins were highly correlated, and common genetic variation explained approximately 71-75% of the variance in iPSC growth rates. These results indicate a complex genetic architecture of iPSC growth rates, where rare, large-effect variants in important growth regulators, including , are layered onto a highly polygenic background. These findings have important implications for the design of pooled iPSC-based studies and disease models, which may be confounded by intrinsic growth differences. - Source: PubMed
Publication date: 2025/07/03
Lee Brian NTaylor Henry JCipriani FilippoNarisu NarisuRobertson Catherine CSwift Amy JSinha NeelamYan TingfenBonnycastle Lori LDale NathanButt AnnieParsaud HemantSemrau Stefan Knowles Joshua WCarcamo-Orive IvanD'Antonio-Chronowska AgnieszkaFrazer Kelly ABiesecker Leslie GNoggle ScottErdos Michael RPaull DanielCollins Francis STaylor D Leland - One of the most common and prevalent cancers is laryngeal squamous cell carcinoma (LSCC), which poses a great threat to the life and health of the patient. Nonetheless, it has been demonstrated that ubiquitination is crucial for the development and course of LSCC. Therefore, it is particularly important to identify biomarkers for ubiquitination-related genes (UbRGs) in LSCC. - Source: PubMed
Publication date: 2025/05/12
Chen QiuWu ZhiminMa Yifei - Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous cancer with limited therapeutic options. Using publicly available datasets, we identified the WD repeat domain 54 (WDR54) gene as a potential therapeutic target in HNSCC. Gene expression profiling interactive analysis version 2 (GEPIA2) was used to identify genes differentially overexpressed in HNSCC. Our results showed that WDR54, a member of the WD40 repeat domain family, was overexpressed in HNSCC tumor samples. Analysis of three gene expression omnibus datasets showed that WDR54 was overexpressed in tumor samples. Using the UALCAN database, we showed that WDR54 expression in patients with HNSCC at different tumor stages gradually increased with disease progression. We confirmed the association between WDR54 and metastasis using TNMplot.com. WDR54 was overexpressed in metastatic samples compared to that in normal and tumor samples. Kaplan-Meier analysis showed that patients with high WDR54 levels had a poorer prognosis. Additionally, WDR54 expression was correlated with the epidermal growth factor receptor, which is frequently overexpressed in HNSCC. Our findings suggest that WDR54 is a promising biomarker and therapeutic target in HNSCC. - Source: PubMed
Publication date: 2024/12/30
Jeong Eun-JeongKim EunjeongKim Yeon Soo